→ The Senate voted to end debate on Scott Gottlieb’s nomination to run the FDA, setting up a final vote that is widely expected to confirm him in the position.
→ Scotland’s Exscientia forged a strategic research deal with Sanofi covering metabolic disease. Exscientia will go to work looking for new bispecifics, and Sanofi will provide research funding and up to €250 million in milestones. Andrew Hopkins, CEO, Exscientia said: “We are delighted that Sanofi is engaging with Exscientia in a comprehensive, end-to-end drug discovery project. This agreement highlights Exscientia’s ability to apply bispecific drug design in a comprehensive and highly productive manner.”
→ Scotland’s Elasmogen and Canada’s Feldan Therapeutics have agreed to collaborate with Amgen, using their technologies to develop the delivery system and binding domains to two undisclosed intracellular targets for Amgen.
→ Sofinnova Ventures, Novo Seeds and Lundbeckfonden Emerge backed a €16.2 million round for Dermtreat ApS, which is developing a patch delivery tech.
The best place to read Endpoints News? In your inbox.
Full-text daily reports for those who discover, develop, and market drugs. Join 17,000+ biopharma pros who read Endpoints News by email every day.Free Subscription